SyntheX

Drugging the undruggable

SyntheX is a company in biopharma based in United States, founded in 2016.

Profile

SyntheX is expanding drug design into the “undruggable” space for the treatment of cancer and rare diseases. We implement an innovative platform for the accelerated discovery of new classes of therapeutics that target the Achilles’ heel of cancer cells in a highly specific and selective manner. At SyntheX, we are expanding the drug discovery space from active site inhibitors to protein-protein interaction modulators using our innovative screening technology.

The company sits in the biopharma segment, where it competes on its core product or service.

United States is where the company is located.

It is recorded at the SOSV portfolio company stage.

Its team size is recorded as 2-10 employees.

Website: synthexlabs.com